Ketamine as Therapy for Resistant Major Depression
the MPR take:
The first study to show benefits of using an intranasal formulation of ketamine for treatment-resistant major depressive disorder has been published in the journal Biological Psychiatry.The double-blind, crossover study, randomized 20 patients with major depressive disorder to receive ketamine (50mg dose) or saline. Depressive symptoms improved significantly in patients given ketamine versus placebo. Out of 18 patients, 8 subjects met response criteria to ketamine within 24 hours of the dose, compared to one in the saline group. The intranasal delivery method is non-invasive, offers quick delivery of the medication, and could improve compliance.
READ FULL ARTICLE From Forbes